Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00176_DB00382_nanopub.RArIzrJVaGFpoVlFn7_bIcslBAmF-OKh_oyh2vPGYML5I#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00176_DB00382 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00176_DB00382 label "DDI between Fluvoxamine and Tacrine - Fluvoxamine, a strong CYP1A2 inhibitor, may decrease the metabolism and clearance of tacrine, a CYP1A2 substrate. Concomitant therapy should be avoided as it could lead to severe toxic effects such as hepatotoxicity. If concomitant therapy is used, monitor for altered efficacy and toxic effects, such as gastrointestinal and hepatic effects, of tacrine. [drugbank_resource:DB00176_DB00382]" assertion.
- drugbank_resource:DB00176_DB00382 identifier "drugbank_resource:DB00176_DB00382" assertion.
- drugbank_resource:DB00176_DB00382 title "DDI between Fluvoxamine and Tacrine - Fluvoxamine, a strong CYP1A2 inhibitor, may decrease the metabolism and clearance of tacrine, a CYP1A2 substrate. Concomitant therapy should be avoided as it could lead to severe toxic effects such as hepatotoxicity. If concomitant therapy is used, monitor for altered efficacy and toxic effects, such as gastrointestinal and hepatic effects, of tacrine." assertion.
- drugbank:DB00382 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00176_DB00382 assertion.
- drugbank:DB00176 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00176_DB00382 assertion.